Europe
Fusion Antibodies plc announces it will release its interim results for the six months ended 30 September 2018 on Monday, 26 November 2018.
Clinical trial authorizations received in all 6 participating countries
Promore Pharma AB, a Swedish biopharmaceutical developer of therapeutic peptides, today announced that the Drug Controller General in India (DCGI) has approved the company’s application to start a clinical Phase III study with PXL01 to prevent post-surgical adhesions after tendon repair surgery.
One in five people with Alzheimer’s disease (AD) who use a benzodiazepine are also concomitant users of an opioid, according to a new study from the University of Eastern Finland.
Continued innovation and technical development means Qualisys can support more applications in diverse industries
GENFIT SA today announced that it plans to conduct a registered public offering of its ordinary shares, in the form of American Depositary Shares (“ADSs”), in the United States and has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission
Three-Year Data from the ANCHOR Registry Reiterate Applicability in Patients with Hostile Aortic Neck Anatomies
MilliporeSigma, a subsidiary of Merck KGaA, Darmstadt, Germany, handed out $30,000 to three graduate students for their research projects.
Vectura was studying VR475, a drug-device combination consisting of budesonide delivered by Vectura’s proprietary nebulizer inhalation system as a treatment for adolescent and adult patients with severe uncontrolled asthma.
Approval is based on Phase 3 SPARTAN clinical study data which showed apalutamide decreased the risk of distant metastasis or death by 72 percent and improved median metastasis-free survival by more than two years
PRESS RELEASES